About Suzetrigine API
Therapeutic CategoryPain Management
CAS Number
2649467‑58‑1
API Technology
Small‑molecule synthetic API
Dose Form
Tablets
Dr Reddy's Development Status
Under Development
Mechanism of action
Suzetrigine selectively inhibits the Naᵥ1.8 voltage‑gated sodium channel, which is predominantly expressed in peripheral pain‑sensing (nociceptive) neurons of the dorsal root ganglia.
It binds to the second voltage‑sensing domain (VSD2) of Naᵥ1.8 and stabilizes the channel in a closed (inactive) state.
Indication
Approved indication (FDA):
Treatment of moderate to severe acute pain in adults
Related APIs
Sumatriptan Succinate
Pain Management
Ketorolac Tromethamine
Pain Management
Naproxen Sodium
Pain Management
Naproxen
Pain Management
Naratriptan Hydrochloride
Pain Management
Suzetrigine
Pain Management
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.